Noxopharm (ASX: NOX) (‘Noxopharm’ or the ‘Company’) today announced the interim three month results from the second part of the DARRT-1 study on its proprietary treatment Veyonda combined with radiotherapy which resulted in reductions in tumour size; reductions in pain for 45% of the men; and reductions in PSA levels for 55% of these men.
The Company’s DARRT (Direct and Abscopal Response to Radiotherapy) Program is testing the ability of Veyonda to increase tumour response to low-dose radiotherapy in prostate cancer.
For more information, download the attached PDF.
Download this document
